Genentech, the venerable biotech unit of Roche, has been cranking out new mobile apps to stay ahead in the biopharma world.
Cancer patients might fail to follow their doctor's orders often. But how often do they forget their mobile phones?
Fresh data have emerged in the ongoing debate over the regulation of medical apps for smartphones and mobile devices. Researchers questioned the accuracy of four apps for evaluating skin lesions in a study, generating some troubling results and pointing out that such apps have gone unregulated.
When a doctor gets a patient with meningitis, she can use a new iPhone app to report the case and location. If the app catches on around the world, as the developers of the app hope, the mobile software could support a global system for real-time infectious disease surveillance.
These apps show just how broad and innovative the life science mobile world has become. Yet each is trying to solve the same critical problem--how can we make drug development more efficient? Here we present 15 mobile apps that tried to answer that question in 2012. Click here to view this slideshow >>
These apps show just how broad and innovative the life science mobile world has become. Yet each is trying to solve the same critical problem - how can we make drug development more efficient? Here we present 15 mobile apps that tried to answer that question in 2012 >>
By Alison Bryant and Daniel Bowman When it comes to the apps game, Big Pharma outfits are stepping up. Companies have added downloadable tools for both providers and patients. Apps range from...
Drug reps can now say, "Check out this useful app." Sounds cooler to us than, "Here's a pen." Check out the slideshow to get a sense for the types of apps drugmakers are pushing these days.
Illumina has ripped a page from Apple's playbook and begun development of an app store for genomics software.
By Jennifer Levin Let's face it, drug developers could use the efficiency that mobile apps promise. With many big market opportunities across the life sciences industry, many firms have either